Erasca, Inc. Contracts & Agreements
36 Contracts & Agreements
- Business Finance (8 contracts)
- Business Operations (2)
- Human Resources (15)
- Intellectual Property (5)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (3)
- Underwriting Agreement, dated May 16, 2024, by and among Erasca, Inc. and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several underwriters... (Filed With SEC on May 17, 2024)
- Stock Purchase Agreement, dated March 27, 2024, by and between Erasca, Inc. and each of the purchasers party thereto (Filed With SEC on March 28, 2024)
- Erasca, Inc. Non-Employee Director Compensation Program (Filed With SEC on March 27, 2024)
- First Amendment to Exclusive License Agreement, dated August 7, 2023, by and between Novartis Pharma AG and the Registrant (Filed With SEC on November 9, 2023)
- Amended and Restated Employment Letter Agreement, dated April 10, 2023, between Shannon R. Morris, M.D., Ph.D. and Erasca, Inc (Filed With SEC on August 10, 2023)
- Underwriting Agreement, dated December 9, 2022, by and among Erasca, Inc. and J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several... (Filed With SEC on December 9, 2022)
- Description of Securities (Filed With SEC on March 24, 2022)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between David M. Chacko, M.D. and the Registrant (Filed With SEC on July 12, 2021)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between Wei Lin, M.D. and the Registrant (Filed With SEC on July 12, 2021)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between Ebun S. Garner and the Registrant (Filed With SEC on July 12, 2021)
- Form of Indemnification Agreement for Directors and Officers (Filed With SEC on July 12, 2021)
- Form of Underwriting Agreement (Filed With SEC on July 12, 2021)
- Erasca, Inc. 2021 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder (Filed With SEC on July 12, 2021)
- Erasca, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on July 12, 2021)
- Erasca, Inc. Severance and Change in Control Severance Plan and Summary Plan Description (Filed With SEC on July 12, 2021)
- Non-Employee Director Compensation Program (Filed With SEC on July 12, 2021)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between Jonathan E. Lim, M.D. and the Registrant (Filed With SEC on July 12, 2021)
- Specimen stock certificate evidencing the shares of common stock (Filed With SEC on June 25, 2021)
- Amended and Restated Stockholders Agreement, dated April 15, 2020, by and among the Registrant and certain of its stockholders (Filed With SEC on June 25, 2021)
- Erasca, Inc. 2018 Equity Incentive Plan, as amended, including form of stock option agreement thereunder (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated February 27, 2020, by and between Jonathan E. Lim, M.D. and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated February 5, 2020, by and between David M. Chacko, M.D. and the Registrant (Filed With SEC on June 25, 2021)
- Release Agreement, dated December 15, 2020, by and between Gary Yeung and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated August 18, 2020, by and between Michael D. Varney, Ph.D. and the Registrant (Filed With SEC on June 25, 2021)
- Scientific Advisory Board Agreement, dated August 15, 2020, by and between Michael D. Varney, Ph.D. and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated November 5, 2020, by and between Wei Lin, M.D. and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated March 27, 2021, by and between Ebun S. Garner and the Registrant (Filed With SEC on June 25, 2021)
- Lease Agreement, dated September 29, 2020 by and between ARE-SD Region No. 23, LLC and the Registrant, as amended (Filed With SEC on June 25, 2021)
- Lease, dated July 27, 2018, by and between BMR-Road to the Cure LP and the Registrant, as amended (Filed With SEC on June 25, 2021)
- Exclusive License Agreement, dated December 21, 2018, by and between The Regents of the University of California and the Registrant, as amended (Filed With SEC on June 25, 2021)
- License Agreement, dated February 18, 2020, by and between NiKang Therapeutics, Inc. and the Registrant (Filed With SEC on June 25, 2021)
- Exclusive License Agreement, dated March 12, 2020, by and between Katmai Pharmaceuticals, Inc. and the Registrant (Filed With SEC on June 25, 2021)
- Licence Agreement, dated April 16, 2020, by and between LifeArc and the Registrant (Filed With SEC on June 25, 2021)
- Agreement and Plan of Merger, dated November 23, 2020, by and among the Registrant and its wholly-owned subsidiaries, ASN Product Development, Inc. and Asana BioSciences, LLC (Filed With SEC on June 25, 2021)
- Amended and Restated License Agreement, dated November 23, 2020, by and among the Registrants wholly-owned subsidiaries, ASN Product Development, Inc. and Asana BioSciences, LLC (Filed With SEC on June 25, 2021)
- Asset Purchase Agreement, dated March 12, 2021, by and between Emerge Life Sciences, PTE, LTD. and the Registrant (Filed With SEC on June 25, 2021)
